Edition:
United States

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

2.71USD
10:40am EST
Change (% chg)

$-0.10 (-3.56%)
Prev Close
$2.81
Open
$2.84
Day's High
$2.84
Day's Low
$2.68
Volume
23,141
Avg. Vol
121,420
52-wk High
$5.10
52-wk Low
$2.20

Latest Key Developments (Source: Significant Developments)

Adamis Pharmaceuticals Announces FDA Acceptance For Review For The Supplemental New Drug Application
Monday, 12 Feb 2018 09:00am EST 

Feb 12 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR REVIEW FOR THE SUPPLEMENTAL NEW DRUG APPLICATION OF ITS LOW DOSE SYMJEPI PRODUCT CANDIDATE.ADAMIS PHARMACEUTICALS CORP - FDA FURTHER INDICATED THAT NO POTENTIAL REVIEW ISSUES WERE IDENTIFIED.ADAMIS PHARMACEUTICALS CORP - FDA FURTHER INDICATED THAT NO POTENTIAL REVIEW ISSUES WERE IDENTIFIED.ADAMIS PHARMACEUTICALS CORP - FDA INDICATED IF NO MAJOR DEFICIENCIES IDENTIFIED, THEY ARE TARGETING SEPTEMBER 3, 2018 TO COMMUNICATE PROPOSED LABELING.  Full Article

Adamis Pharmaceuticals Announces Submission Of Investigational New Drug (Ind) Application To The FDA
Monday, 4 Dec 2017 04:05pm EST 

Dec 4 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE FDA FOR NEW PRODUCT CANDIDATE FOR THE TREATMENT OF OPIOID OVERDOSE.  Full Article

Adamis Pharma Submits Prior Approval Supplement To FDA For The Pediatric Version Of Symjepi
Wednesday, 29 Nov 2017 04:05pm EST 

Nov 29 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS SUBMITS PRIOR APPROVAL SUPPLEMENT TO FDA FOR THE PEDIATRIC VERSION OF SYMJEPI.ADAMIS PHARMACEUTICALS CORP - SUBMISSION OF A PRIOR APPROVAL SUPPLEMENT TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDIATRIC VERSION (0.15MG) OF SYMJEPI.  Full Article

Adamis Pharmaceuticals gets FDA approval for co's epinephrine pre-filled syringe
Thursday, 15 Jun 2017 02:31pm EDT 

June 15 (Reuters) - Adamis Pharmaceuticals Corp ::Adamis pharmaceuticals receives FDA approval for its epinephrine pre-filled syringe.Adamis pharmaceuticals receives FDA approval for its epinephrine pre-filled syringe.FDA has also approved PFS trade name of Symjepi.‍FDA approved Adamis' epinephrine injection, USP, 1:1000 for emergency treatment of allergic reactions including anaphylaxis​.Are preparing to submit second NDA for junior version of Symjepi to FDA.Expect to build inventory levels in preparation for anticipated launch in H2 of year for co's epinephrine pre-filled syringe.  Full Article

Perceptive Advisors reports 5.57 pct stake in Adamis Pharma
Monday, 24 Apr 2017 09:21am EDT 

April 24 (Reuters) - Adamis Pharmaceuticals Corp ::Perceptive Advisors LLC reports 5.57 percent passive stake in Adamis Pharmaceuticals Corp as of April 21 - SEC filing.  Full Article

Adamis Pharmaceuticals announces pricing of public offering of common stock
Friday, 21 Apr 2017 09:13am EDT 

April 21 (Reuters) - Adamis Pharmaceuticals Corp :Adamis Pharmaceuticals announces pricing of public offering of common stock.Says public offering of 4.29 million common shares priced at $3.50per share.Adamis Pharmaceuticals Corp - Offering is expected to close on April 26, 2017.  Full Article

Adamis Pharmaceuticals announces proposed public offering of common stock
Thursday, 20 Apr 2017 04:01pm EDT 

April 20 (Reuters) - Adamis Pharmaceuticals Corp -:Adamis Pharmaceuticals announces proposed public offering of common stock.Adamis Pharmaceuticals -intends to use net proceeds for general corporate purposes, which may includeexpenditures relating to research, among others.  Full Article

Swiss stocks - Factors to watch on Dec. 7

ZURICH/BERLIN, Dec 7 The Swiss blue-chip SMI was seen opening 1.2 percent higher at 8,765 points on Friday, according to premarket indications by bank Julius Baer .